and Herpes simplex virus (HSV). Of these, the furthest ahead in development is the RSV vaccine, which could launch later this year and would compete with products from GSK and Pfizer based on ...
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK blames political and regulatory pressures ... with Zhifei now set to purchase 21.6bn yuan ($2.97bn) worth of the vaccine over six years. The revision follows a sharp downturn in China ...
GSK has counted the cost of narrower US recommendations on the use of RSV vaccines, which caused a 51% decline in sales of its Arexvy shot in 2024, but still managed to post reasonable sales ...
Wednesday, GSK Plc (NYSE:GSK ... The analysts estimated sales of $9.58 billion. Vaccine sales fell 14% (-11% at constant currency) to 2.21 billion pounds, primarily impacted by lower demand ...
Vivian Wan / Bloomberg via Getty Images GSK ... 18 months of 2 billion pounds ($2.5 billion). The company said it expects 2025 revenue to grow between 3% and 5%, even with vaccine sales likely ...
GSK reported Q4 sales of $10.40B, surpassing estimates of $9.58B, while core EPS of $0.59 beat the consensus of $0.43 despite a 10% decline. Vaccine sales fell 14% to £2.21B, with Arexvy sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback